APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia

Abstract
The E4 allele of the apolipoprotein E gene (APOE) has been established as a genetic risk factor for many diseases including cardiovascular diseases and Alzheimer’s disease (AD), yet its mechanism of action remains poorly understood. APOE is a lipid transport protein, and the dysregulation of lipids has recently emerged as a key feature of several neurodegenerative diseases including AD. However, it is unclear how APOE4 perturbs the intracellular lipid state. Here, we report that APOE4, but not APOE3, disrupted the cellular lipidomes of human induced pluripotent stem cell (iPSC)–derived astrocytes generated from fibroblasts of APOE4 or APOE3 carriers, and of yeast expressing human APOE isoforms. We combined lipidomics and unbiased genome-wide screens in yeast with functional and genetic characterization to demonstrate that human APOE4 induced altered lipid homeostasis. These changes resulted in increased unsaturation of fatty acids and accumulation of intracellular lipid droplets both in yeast and in APOE4-expressing human iPSC-derived astrocytes. We then identified genetic and chemical modulators of this lipid disruption. We showed that supplementation of the culture medium with choline (a soluble phospholipid precursor) restored the cellular lipidome to its basal state in APOE4-expressing human iPSC-derived astrocytes and in yeast expressing human APOE4. Our study illuminates key molecular disruptions in lipid metabolism that may contribute to the disease risk linked to the APOE4 genotype. Our study suggests that manipulating lipid metabolism could be a therapeutic approach to help alleviate the consequences of carrying the APOE4 allele.
Funding Information
  • National Institutes of Health
  • Howard Hughes Medical Institute
  • Howard Hughes Medical Institute
  • National Institute of Mental Health
  • National Heart, Lung, and Blood Institute
  • National Human Genome Research Institute
  • National Institute of Neurological Disorders and Stroke (ALTF 829-2015)
  • National Institute of Neurological Disorders and Stroke (NIH/NIA K99)
  • National Institute of Neurological Disorders and Stroke (AG055697-03)
  • National Institute of Neurological Disorders and Stroke (R01 CA103866)
  • National Institute of Neurological Disorders and Stroke (RF1 AG048029)
  • National Institute of Neurological Disorders and Stroke (RF1 AG062377)
  • National Institute of Neurological Disorders and Stroke (U01 NS110453)
  • National Institute of Neurological Disorders and Stroke (R01 AG062335)
  • National Institute of Neurological Disorders and Stroke (R01 AG058002)
  • NIH Office of the Director
  • National Institute of Neurological Disorders and Stroke
  • NIH Office of the Director (AG055697-03)
  • National Cancer Institute, Cairo University
  • National Institute of Development Administration
  • Neurodegeneration Consortium
  • NIH Clinical Center (R01 CA103866)
  • Damon Runyon Cancer Research Foundation
  • European Molecular Biology Organization (ALTF 829-2015)
  • Helen Hay Whitney Foundation
  • Alzheimer’s Association (AARF-19-616816)
  • Helen Hay Whitney Foundation
  • Neurodegeneration Consortium
  • NIH Blueprint for Neuroscience Research (R01 AG062335)
  • NIH Blueprint for Neuroscience Research (R01 AG058002)
  • NIH Blueprint for Neuroscience Research (RF1 AG048029)
  • NIH Blueprint for Neuroscience Research (RF1 AG062377)
  • Robert A. and Renee E. Belfer Family Foundation